MedBodh Medical News | 24 October 2026 | WHO Update
Nearly half of the world’s population has little or no access to safe, affordable, quality-assured diagnostic services, according to the World Health Organization (WHO). On 22 October 2026, WHO’s Global Diagnostics Coalition called for coordinated action to close this gap. Diagnostics are not a luxury: they guide screening, diagnosis, treatment selection, monitoring and referral.
Quick Note Sheet
- WHO update: 22 October 2026.
- Headline gap: an estimated 47% of the world’s population has little or no access to safe, affordable, quality-assured diagnostics.
- Estimated benefit: closing key diagnostic gaps in low- and middle-income countries could avert around 1.1 million premature deaths annually.
- What counts as diagnostics? Laboratory tests, point-of-care tests, medical imaging, blood-pressure measurement, ECG and other tools.
- Clinical message: test availability alone is insufficient; reliable results, timely interpretation and action are essential.
What WHO announced
The WHO-managed Global Diagnostics Coalition is an informal network bringing together governments, professional bodies, international organizations, civil society, academia and industry. Its purpose is to increase visibility of diagnostic gaps, support national policy integration and encourage practical collaboration. The coalition was launched in May 2025; the October 2026 communication is a call to accelerate action, not the launch of a new test or treatment.
The diagnostic access gap: key figures
| WHO figure | Interpretation |
|---|---|
| 47% | Estimated global population with little or no access to reliable, affordable, quality-assured diagnostic services |
| 81% | Basic primary healthcare services without essential diagnostics in a study of 14 LMICs, excluding HIV and malaria testing |
| <1 vs ~40 | CT scanners per million people in lower/middle-income settings versus high-income countries, as summarized by WHO |
| 1.1 million | Estimated premature deaths per year potentially avertable by closing selected diagnostic gaps in LMICs |
These estimates describe different populations, settings and analytical methods. They must not be presented as measured figures for India, Uttarakhand or an individual district.
Why timely diagnosis matters
1. Infectious diseases
Appropriate microbiology and point-of-care testing can help distinguish causes of illness, support targeted treatment and reduce unnecessary antibiotic exposure. Test choice must follow clinical severity and local guidelines; unstable patients must not wait for testing before urgent resuscitation and indicated treatment.
2. Hypertension and cardiovascular disease
Accurate blood-pressure measurement, ECG and indicated laboratory investigations help identify risk and complications. A single elevated BP reading does not always establish chronic hypertension; repeat measurement and clinical context are important.
3. Diabetes
Validated glucose and HbA1c testing, when appropriate, support diagnosis and long-term monitoring. Test quality, calibration and clinical interpretation affect patient care.
4. Maternal and newborn health
Haemoglobin testing, blood grouping, infection screening and appropriately indicated ultrasound can support antenatal risk assessment. The diagnostic package depends on national guidance, gestational age and the patient’s clinical situation.
5. Tuberculosis and cancer
Timely access to recommended TB diagnostic tests and appropriate cancer screening, imaging and pathology can reduce delays. Screening is not equivalent to confirmed diagnosis; referral completion is essential.
What should PHCs and CHCs prioritise?
| System component | Practical action |
|---|---|
| Essential test menu | Match tests to services offered, national protocols and disease burden |
| Quality assurance | Internal quality control, external assessment where applicable, maintenance and calibration |
| Turnaround time | Track time from request to clinically actionable result |
| Staff capacity | Train personnel in collection, biosafety, documentation and interpretation |
| Stock and equipment | Monitor reagent stock-outs, expiry, cold chain and machine downtime |
| Referral | Provide reliable specimen transport and referral pathways for unavailable tests |
| Patient communication | Ensure results are communicated and abnormal findings receive follow-up |
Practical 30-day diagnostic improvement plan
- Week 1: audit the ten most frequently ordered tests, stock-outs, machine downtime and rejected specimens.
- Week 2: verify quality-control procedures, sample labelling, reporting pathways and urgent-result escalation.
- Week 3: review whether abnormal results lead to clinician assessment and completed referrals.
- Week 4: display a simple dashboard: test availability, turnaround time, rejected samples, downtime and critical-result communication.
This is a suggested quality-improvement framework for local adaptation, not a WHO-mandated 30-day programme.
How the Global Diagnostics Coalition works
The coalition organizes its work around evidence, advocacy and integration. Its thematic areas include data gaps, learning and knowledge sharing, political prioritization, primary healthcare integration, workforce and quality systems, and supply chains and innovation. Stronger diagnostic access requires coordinated action across procurement, training, regulation, laboratories, imaging and clinical services.
Important limitations
- The 47% estimate does not mean 47% of people have no healthcare at all; it specifically concerns access to reliable diagnostic services.
- Access varies across countries, regions, tests and clinical settings.
- The announcement does not create a new Indian testing mandate or change individual treatment guidelines.
- Diagnostic expansion must be coupled with quality assurance, patient safety and follow-up.
Frequently asked questions
What are essential diagnostics?
Priority tests and technologies needed to support common clinical decisions, adapted to the level of care and national recommendations.
Does a new machine alone solve the diagnostic gap?
No. Staff, reagents, maintenance, quality control, result interpretation and referral systems are also required.
Are all diagnostic tests laboratory tests?
No. Imaging, ECG, blood-pressure devices and other in-vivo and point-of-care tools are included.
Is this a new WHO clinical guideline?
No. It is a public-health and health-systems call to action.
References and primary sources
- WHO departmental update: Global Diagnostics Coalition calls for collective action (22 October 2026)
- WHO: Global Diagnostics Coalition — overview and statistics
- WHO: Diagnostics — health topic overview
Editorial disclaimer: For healthcare education and service planning. Local diagnostic protocols, test availability and patient-specific clinical judgement take precedence.